title: Physiologically based biokinetic (PBBK) model for safrole bioactivation and detoxification in rats.
abstract: A physiologically based biokinetic (PBBK) model for alkenylbenzene safrole in rats was developed using in vitro metabolic parameters determined using relevant tissue fractions. The performance of the model was evaluated by comparison of the predicted levels of 1,2-dihydroxy-4-allylbenzene and 1'-hydroxysafrole glucuronide to levels of these metabolites reported in the literature to be excreted in the urine of rats exposed to safrole and by comparison of the predicted amount of total urinary safrole metabolites to the reported levels of safrole metabolites in the urine of safrole exposed rats. These comparisons revealed that the predictions adequately match observed experimental values. Next, the model was used to predict the relative extent of bioactivation and detoxification of safrole at different oral doses. At low as well as high doses, P450 mediated oxidation of safrole mainly occurs in the liver in which 1,2-dihydroxy-4-allylbenzene was predicted to be the major P450 metabolite of safrole. A dose dependent shift in P450 mediated oxidation leading to a relative increase in bioactivation at high doses was not observed. Comparison of the results obtained for safrole with the results previously obtained with PBBK models for the related alkenylbenzenes estragole and methyleugenol revealed that the overall differences in bioactivation of the three alkenylbenzenes to their ultimate carcinogenic 1'-sulfooxy metabolites are limited. This is in line with the generally less than 4-fold difference in their level of DNA binding in in vitro and in vivo studies and their almost similar BMDL(10) values (lower confidence limit of the benchmark dose that gives 10% increase in tumor incidence over background level) obtained in in vivo carcinogenicity studies. It is concluded that in spite of differences in the rates of specific metabolic conversions, overall the levels of bioactivation of the three alkenylbenzenes are comparable which is in line with their comparable carcinogenic potential.
authors: Division of Toxicology, Wageningen University, Tuinlaan 5, 6703 HE Wageningen, The Netherlands. erryana.martati@wur.nl
authors: E
authors: E
authors: Martati
authors: M G
authors: MG
authors: Boersma
authors: A
authors: A
authors: Spenkelink
authors: D B
authors: DB
authors: Khadka
authors: A
authors: A
authors: Punt
authors: J
authors: J
authors: Vervoort
authors: P J
authors: PJ
authors: van Bladeren
authors: I M C M
authors: IM
authors: Rietjens
mesh_terms: D000498:Allyl Compounds / Q000378:metabolism; D000081248:Allylbenzene Derivatives; D000818:Animals; D000840:Anisoles / Q000378:metabolism; D001555:Benzene Derivatives / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D005054:Eugenol / Q000031:analogs & derivatives / Q000378:metabolism; D005503:Food Additives / Q000378:metabolism*; D020719:Glucuronides / Q000378:metabolism; D007700:Kinetics; D008297:Male; D008954:Models, Biological; D009153:Mutagens / Q000378:metabolism*; D010084:Oxidation-Reduction; D051381:Rats; D017207:Rats, Sprague-Dawley; D012451:Safrole / Q000031:analogs & derivatives* / Q000378:metabolism*
chemical_list: D000498:Allyl Compounds; D000081248:Allylbenzene Derivatives; D000840:Anisoles; D001555:Benzene Derivatives; D005503:Food Additives; D020719:Glucuronides; D009153:Mutagens; C005223:methyleugenol; C102347:allylbenzene; D005054:Eugenol; D003577:Cytochrome P-450 Enzyme System; C007633:estragole; C012376:1'-hydroxysafrole; D012451:Safrole